Natera, Inc. (NASDAQ:NTRA) CEO Steven Leonard Chapman Sells 4,523 Shares of Stock

Natera, Inc. (NASDAQ:NTRA) CEO Steven Leonard Chapman sold 4,523 shares of the company’s stock in a transaction dated Tuesday, October 15th. The stock was sold at an average price of $130.40, for a total transaction of $589,799.20. Following the completion of the transaction, the chief executive officer now owns 191,163 shares in the company, valued at approximately $24,927,655.20. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Steven Leonard Chapman also recently made the following trade(s):

• On Monday, September 16th, Steven Leonard Chapman sold 5,024 shares of Natera stock. The shares were sold at an average price of $128.48, for a total transaction of $645,483.52.
• On Thursday, August 15th, Steven Leonard Chapman sold 5,583 shares of Natera stock. The shares were sold at an average price of $118.91, for a total transaction of $663,874.53.
• On Monday, July 29th, Steven Leonard Chapman sold 4,084 shares of Natera stock. The stock was sold at an average price of $102.77, for a total transaction of $419,712.68.
• On Monday, July 22nd, Steven Leonard Chapman sold 2,638 shares of Natera stock. The stock was sold at an average price of $105.16, for a total value of $277,412.08.

Natera Trading Down 3.5 %

Shares of NASDAQ:NTRA opened at $122.35 on Friday. The firm has a market capitalization of $15.02 billion, a price-to-earnings ratio of -39.21 and a beta of 1.53. The business’s 50 day moving average price is $123.15 and its 200-day moving average price is $110.16. The company has a debt-to-equity ratio of 0.34, a current ratio of 4.14 and a quick ratio of 4.01. Natera, Inc. has a 1 year low of $36.90 and a 1 year high of $133.54.

Natera (NASDAQ:NTRA) last announced its earnings results on Thursday, August 8th. The medical research company reported ($0.30) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.69) by $0.39. Natera had a negative net margin of 21.47% and a negative return on equity of 36.74%. The business had revenue of $413.35 million for the quarter, compared to analyst estimates of $343.00 million. During the same quarter last year, the business earned ($0.97) earnings per share. The company’s revenue for the quarter was up 58.1% compared to the same quarter last year. On average, equities research analysts forecast that Natera, Inc. will post -1.96 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several brokerages recently weighed in on NTRA. UBS Group dropped their target price on Natera from $160.00 to $145.00 and set a “buy” rating on the stock in a research note on Friday, August 9th. TD Cowen upped their price objective on shares of Natera from $137.00 to $145.00 and gave the company a “buy” rating in a report on Friday, August 9th. Stephens reiterated an “overweight” rating and issued a $125.00 target price on shares of Natera in a research note on Friday, August 9th. StockNews.com upgraded shares of Natera from a “sell” rating to a “hold” rating in a research note on Thursday. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $150.00 price target on shares of Natera in a report on Friday, September 13th. One analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. According to data from MarketBeat, Natera has a consensus rating of “Moderate Buy” and a consensus target price of $124.44.

Institutional Investors Weigh In On Natera

Several large investors have recently bought and sold shares of the company. SG Americas Securities LLC boosted its stake in shares of Natera by 1,073.1% in the second quarter. SG Americas Securities LLC now owns 65,730 shares of the medical research company’s stock worth $7,118,000 after acquiring an additional 60,127 shares during the last quarter. Russell Investments Group Ltd. grew its stake in Natera by 15.1% during the 1st quarter. Russell Investments Group Ltd. now owns 74,460 shares of the medical research company’s stock valued at $6,810,000 after acquiring an additional 9,781 shares in the last quarter. Natixis acquired a new stake in Natera in the 1st quarter valued at about $758,000. Allspring Global Investments Holdings LLC lifted its stake in Natera by 19.9% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 863,406 shares of the medical research company’s stock worth $78,967,000 after purchasing an additional 143,246 shares in the last quarter. Finally, Baader Bank Aktiengesellschaft acquired a new position in shares of Natera during the 2nd quarter worth approximately $478,000. 99.90% of the stock is currently owned by hedge funds and other institutional investors.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.